The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Sang, I am sure you appreciate that the end users have many different ways of working. Angle has had to become better at matching these differing requirements. Hence the "kits" which are much more challenging to develop than "regular assays" and of course Next Generation Sequencing. Angle have informed the market that they have been engaged in all three in recent month. I think it is more of a case that we as investors are beginning to understand what the company has achieved over the last year or so.
Sang,
The Solaris trial has been fully recruited (100 subjects ) as per webinar Sep 23, and presentations since, and the deck of slides that accompany them, and the company website. We are awaiting results which may take some time, depending on which platform is or will be used to present them. Although there is a MHRA link which shows the trial as being terminated due to low recruitment, I am happy with all the multiple evidence that there are 100 subjects that have provided samples and I will wait.
I am in Angle and the share price has had a good rise in the last week. Not quite the levels of OBD mind. I can honestly say at no time did any of us know where the share price was headed and still don't! This is because shares often do better rising on potential than reality. What you are talking about is a valuation based on reality and not potential (as facts become clear of drug utility). Err, I don't know, potential seems to do ok to be honest. IMO.
Hi TGTD,
That is the point. The results of the 47 subjects are scaleable. There really is no reason not to add Parsortix to NGS is there. However this is just one route to market for Parsortix, but it is very direct and straightforward. I agree with Bermuda Shorts, it will take time for everyone to realise what these results actually mean.
ATB
Thanks Bermuda for your view. Very much appreciated. A few of us have made a bit of a leap in understanding today regarding NGS.
I also found this very helpful:
https://youtu.be/WKAUtJQ69n8?si=-DSGOK3gKvO3xZVE
At first I presumed incorrectly that an assay would be used with a third party system as Angle are aiming for with the prostate and ovarian study. But this route seems a lot more direct and an excellent route to market.
As ever with Angle, the devil is in the detail.
ATB
Wondering if you can help...
Regarding the Illumina NGS results achieved in 47 subjects. Can you confirm my understanding that NGS requires a series of steps rather than an assay (that Angle would either buy of the shelf or develop it's own). Or, do you think it is possible that Angle could/have used an assay in combination. Is that even something that is done? I have asked IG today by email so lets see what he says too. I was rather hoping at first that Angle might have developed it's first molecular assay but I think that is unlikely. Would appreciate your views.
ATB
2023 Avacta maintained an average share price of £1.25 with 283 million shares in issue.
Scancell sits at 11p with four times as many shares fully diluted (1.2 Billion)
So if you divide £1.25 by four (to give a comparable share issue to Avacta) it gives an average share price of 31p for SCLP.
Or if you times 11p by four you get an Avacta share price of 44p. However as stated, Avacta has been hanging around £1.25 for a year or so, which in my book makes it a fact on which too base a reasonable estimate of where two separate companies with equalled out share capital and prospects should stand
Here we sit at 11p...
Https://www.msn.com/en-gb/health/other/woman-struck-twice-by-tonsil-cancer-celebrates-as-tumour-shrinks-in-half/ar-AA1m7rHL?ocid=socialshare
Probably not us as the timings and size of trial may not be right. Also phase 2 Head and neck. But good to see things working for the patient
Exactly Mia thanks. 927 million shares in issue so I guess that is it? Dont get me wrong I would prefer 200 million but obviously not the case. I did see someone mentioned that Scancell would have 1.2 billion shares in issue following the raise but guess that is wrong or am I missing something?
Hi TF,
Balance on my investment platforms today indicates that I have been debited for the open offer. I am expecting an RNS Tuesday 19th. Slightly curious to see which direction the SP goes up until Friday but for me it is all about Jan when the market steps into a more regular rhythm.
Good points raised by Inan, Burble, and excellent questions from RR. Nice to be cashed up as you say with a good trajectory for SCIB1. Really looking for iSCIB1+ to work out which is not a given and also durable response is my main focus now.
We know that cancer can evade the immune system and that in such instances when drugs are used, especially novels ones, cancer seems especially adept at evading them. So you could say that with a cancer that is smart enough to seed, it is little wonder that it can evade drugs.
So, my question is this. SCIB1 is demonstrating success in several types of outcome measures including ORR and tumour burden. Granted, it must demonstrate a durable response, but why is it successful so far? Reminder the expected outcomes for novel drugs is extremely poor.
Many thanks in advance